OrsoBio, Inc

OrsoBio is a clinical-stage biopharmaceutical company dedicated to developing first-in-class therapies to treat severe metabolic disorders by addressing their root causes. Their mission is to redefine treatment by targeting fundamental pathways of energy metabolism with innovative therapies. The company has a diverse pipeline of programs including ACC2 inhibitors, LXR inverse agonists, mitochondrial protonophores, and ACMSD inhibitors, aimed at conditions such as obesity, diabetes, dyslipidemias, NASH, and organ failure. With a team of experienced physicians and scientists, and collaborations with leading academic institutions and investors, OrsoBio is committed to advancing therapies that restore energy homeostasis and improve patient outcomes.